Angiomyxoma of the pelvis in women. Clinical cases
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.234
Abstract
Aggressive pelvic angiomyxoma belongs to one of the rare types of mesenchymal pelvic tumors found in premenopause patients. Currently, this pathology is mainly treated via surgical intervention. Alternatively, it may also be managed by using radiation or hormone therapy. The final diagnosis is usually established by histological examination of removed tumor, because biopsy analysis during examination may not always provide a high diagnostic value. This tumor type is able to relapse, even after 100 % surgically removed intervention. Immunohistochemistry examination reveals expression of progesterone and estrogen receptors. One of the hormone therapy options with good long-term effect is based on using gonadotropin-releasing hormone drugs. Taking into consideration slow tumor growth and hormonal sensitivity, one of the options for managing disease relapse is patient follow-up, especially in perimenopausal subjects. Single clinical cases have been published related to pelvic angiomyxoma so that it results in introducing individualized management for every certain patient, but unified therapeutic approaches have not been developed yet.
About the Authors
E. V. Slukhanchuk
Petrovsky National Research Centre of Surgery;
Sechenov University
Russian Federation
Russian Federation
Ekaterina V. Slukhanchuk – MD, PhD, Obstetrician-Gynecologist, Department of Abdominal Surgery and Oncology 2, Petrovsky National Research Centre of Surgery; Associate Professor, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s Health, Sechenov University
2 Abrikosovskiy Lane, Moscow 119991,
2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991
A. G. Tyan
Petrovsky National Research Centre of Surgery
Russian Federation
Russian Federation
Anatoly G. Tyan – MD, PhD, Chief Physician
2 Abrikosovskiy Lane, Moscow 119991
A. L. Bedzhanyan
Petrovsky National Research Centre of Surgery;
Sechenov University
Russian Federation
Russian Federation
Arkady L. Bedzhanyan – MD, Dr Sci Med, Head of the Department оf Abdominal Surgery and Oncology 2, Petrovsky National Research Centre of Surgery; Associate Professor, Department of Hospital Surgery, Sechenov University
2 Abrikosovskiy Lane, Moscow 119991,
2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991
L. M. Nechitaylo
Petrovsky National Research Centre of Surgery
Russian Federation
Russian Federation
Lidia M. Nechitaylo – MD, Obstetrician-Gynecologist
2 Abrikosovskiy Lane, Moscow 119991,
O. V. Dolzhanskiy
Petrovsky National Research Centre of Surgery
Russian Federation
Russian Federation
Oleg V. Dolzhanskiy – MD, Dr Sci Med, Head of the Department of Pathological Anatomy
2 Abrikosovskiy Lane, Moscow 119991,
T. N. Galyan
Petrovsky National Research Centre of Surgery
Russian Federation
Russian Federation
Tatiana N. Galyan – MD, PhD, Physician, Department of Radiation Diagnostics and Computed Tomography
2 Abrikosovskiy Lane, Moscow 119991,
References
1. Steeper T.A., Rosai J. Aggressive angiomyxoma of the female pelvis and perineum. Report of nine cases of a distinctive type of gynecologic softtissue neoplasm. Am J Surg Pathol. 1983;7(5):463–75. https://doi.org/10.1097/00000478-198307000-00009.
2. Fetsch J.F., Laskin W.B., Lefkowitz M. et al. Aggressive angiomyxoma: a clinicopathologic study of 29 female patients. Cancer. 1996;78(1):79–90. https://doi.org/10.1002/(SICI)1097-0142(19960701)78:1<79::AIDCNCR13>3.0.CO;2-4.
3. Vickie Y.Jo., Fletcher Сh.D.M. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology. 2014;46(2):95–104. https://doi.org/10.1097/PAT.0000000000000050.
4. Linares E.E., Abbad D.R., van de Brule R.M. et al. Aggressive pelvic angiomyxoma. Archivos Espanoles de Urologia. 2014;67(3):288–90.
5. Haldar K., Martinek I., Kehoe S. Aggressive angiomyxoma: a case series and literature review. Eur J Surg Oncol. 2010;36(4):335–9. https://doi.org/10.1016/j.ejso.2009.11.006.
6. Neyaz A., Husain N., Anand N., Srivastava P. Rare paratesticular aggressive angiomyxoma with negative oestrogen and progesterone receptors in a male patient. BMJ Case Rep. 2018;2018:bcr2017222164. https://doi.org/10.1136/bcr-2017-222164.
7. Aydin A.M., Katipoglu K., Baydar D.E., Bilen C.Y. Long-standing aggressive angiomyxoma as a paratesticular mass: a case report and review of literature. SAGE Open Med Case Rep. 2017;5:2050313X17712090. https://doi.org/10.1177/2050313X17712090.
8. Bai H., Yang J., Huang H. et al. Individualized managing strategies of aggressive angiomyxoma of female genital tract and pelvis. Eur J Surg Oncol. 2013;39(10):1101–8. https://doi.org/10.1016/j.ejso.2013.06.013.
9. Suleiman M., Duc C., Ritz S., Bieri S. Pelvic excision of large aggressive angiomyxoma in a woman: irradiation for recurrent disease. Int J Gynecol Cancer. 2006;16(Suppl 1):356–60. https://doi.org/10.1111/j.1525-1438.2006.00218.x.
10. Chan I.M., Hon E., Ngai S.W. et al. Aggressive angiomyxoma in females: is radical resection the only option? Acta Obstet Gynecol Scand. 2000;79(3):216–20.
11. Fine B.A., Munoz A.K., Litz C.E., Gershenson D.M. Primary medical management of recurrent aggressive angiomyxoma of the vulva with a gonadotropin-releasing hormone agonist. Gynecol Oncol. 2001;81(1):120– 2. https://doi.org/10.1006/gyno.2000.6119.
12. Coppola S., Desai A., Tzanis D. et al. Conservative en bloc surgery for aggressive angiomyxoma achieves good local control: analysis of 14 patients from a single institution. Int J Gynecol Cancer. 2013;23(3):540–5. https://doi.org/10.1097/IGC.0b013e3182843063.
Review
For citations:
Slukhanchuk E.V., Tyan A.G., Bedzhanyan A.L., Nechitaylo L.M., Dolzhanskiy O.V., Galyan T.N. Angiomyxoma of the pelvis in women. Clinical cases. Obstetrics, Gynecology and Reproduction. 2021;15(5):617-626. (In Russ.) https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.234
Views:
978
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
